DK3078376T3 - Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme - Google Patents

Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme Download PDF

Info

Publication number
DK3078376T3
DK3078376T3 DK16161921.8T DK16161921T DK3078376T3 DK 3078376 T3 DK3078376 T3 DK 3078376T3 DK 16161921 T DK16161921 T DK 16161921T DK 3078376 T3 DK3078376 T3 DK 3078376T3
Authority
DK
Denmark
Prior art keywords
methylphenyl
imidazole
methanol
ethyl
treatment
Prior art date
Application number
DK16161921.8T
Other languages
English (en)
Inventor
Mohammed I Dibas
Daniel W Gil
Ken Chow
Liming Wang
Michael E Garst
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3078376(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK3078376T3 publication Critical patent/DK3078376T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK16161921.8T 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme DK3078376T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
EP11760958.6A EP2616066B1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating retinal diseases

Publications (1)

Publication Number Publication Date
DK3078376T3 true DK3078376T3 (da) 2019-06-24

Family

ID=44675870

Family Applications (9)

Application Number Title Priority Date Filing Date
DK16161920.0T DK3050563T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande
DK16161921.8T DK3078376T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK16161923T DK3050564T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK19194325.7T DK3636263T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK18157147.2T DK3338777T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK16161922.6T DK3053576T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760963.6T DK2616069T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
DK18160174.1T DK3348264T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760962.8T DK2616068T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK16161920.0T DK3050563T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande

Family Applications After (7)

Application Number Title Priority Date Filing Date
DK16161923T DK3050564T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK19194325.7T DK3636263T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK18157147.2T DK3338777T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK16161922.6T DK3053576T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760963.6T DK2616069T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
DK18160174.1T DK3348264T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760962.8T DK2616068T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk

Country Status (29)

Country Link
US (9) US8653123B2 (da)
EP (13) EP2616066B1 (da)
JP (4) JP6045495B2 (da)
KR (7) KR101840501B1 (da)
CN (5) CN103221045A (da)
AR (4) AR083019A1 (da)
AU (4) AU2011301847B2 (da)
BR (4) BR112013006320B1 (da)
CA (8) CA3116249A1 (da)
CL (4) CL2013000736A1 (da)
CY (3) CY1121024T1 (da)
DK (9) DK3050563T3 (da)
ES (10) ES2607084T3 (da)
HK (5) HK1185540A1 (da)
HU (5) HUE047476T2 (da)
IL (4) IL225282A0 (da)
MX (4) MX2013003004A (da)
MY (4) MY161607A (da)
NZ (1) NZ608751A (da)
PL (7) PL3338777T3 (da)
PT (7) PT3050564T (da)
RU (4) RU2013116405A (da)
SG (4) SG188573A1 (da)
SI (5) SI3348264T1 (da)
TR (1) TR201909249T4 (da)
TW (4) TWI591058B (da)
UA (1) UA112973C2 (da)
WO (4) WO2012037484A1 (da)
ZA (4) ZA201302194B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395999B1 (en) 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
US9095576B2 (en) 2011-11-21 2015-08-04 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
US20240287093A1 (en) * 2018-08-24 2024-08-29 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
MX2023012132A (es) * 2021-04-16 2023-10-25 Ads Therapeutics Llc Cofarmacos agonistas alfa-2 adrenergicos conjugados con farmacos agonistas muscarinicos.
WO2024167962A1 (en) * 2023-02-08 2024-08-15 Whitecap Biosciences Llc Alpha-2-adrenergic agonists for improving vision

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642332B1 (en) 1992-05-13 1997-01-15 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
EP0729459B1 (en) 1993-11-15 2003-03-12 Schering Corporation Phenyl-alkyl imidazoles as h3-receptor antagonists
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
MXPA05012679A (es) * 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
JP2007528020A (ja) * 2003-07-14 2007-10-04 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 投影装置
KR20060126448A (ko) 2003-09-12 2006-12-07 알러간, 인코포레이티드 통증 및 다른 알파 2 아드레날린 매개 증상을 치료하기위한 방법 및 조성물
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP4955543B2 (ja) * 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
BRPI0516083A (pt) * 2004-09-24 2008-08-19 Allergan Sales Inc 4-(fenilmetil e 4-fenilmetil substituìdo)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
US20110306635A1 (en) 2009-02-06 2011-12-15 Allergan ,Inc. Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors
EP2395999B1 (en) * 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Also Published As

Publication number Publication date
ES2737230T3 (es) 2020-01-10
EP3050563B1 (en) 2018-05-09
AU2011301856A1 (en) 2013-05-02
CN103221045A (zh) 2013-07-24
BR112013006320A2 (pt) 2016-06-21
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
US8492422B2 (en) 2013-07-23
US8653123B2 (en) 2014-02-18
DK3348264T3 (da) 2020-03-23
AR083020A1 (es) 2013-01-23
EP3659600A1 (en) 2020-06-03
SI3050563T1 (sl) 2018-10-30
TW201305117A (zh) 2013-02-01
DK2616069T3 (da) 2016-12-19
US20120149746A1 (en) 2012-06-14
WO2012037453A1 (en) 2012-03-22
US20120136036A1 (en) 2012-05-31
MX2013003009A (es) 2013-06-28
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
EP3698789A1 (en) 2020-08-26
CA3122745A1 (en) 2012-03-22
CN103200941A (zh) 2013-07-10
ES2593612T3 (es) 2016-12-12
SG188573A1 (en) 2013-04-30
EP3348264A1 (en) 2018-07-18
KR102104760B1 (ko) 2020-04-27
MY191369A (en) 2022-06-20
DK3050563T3 (da) 2018-08-13
CN103200941B (zh) 2015-12-16
BR112013006352A2 (pt) 2016-06-28
EP3348264B1 (en) 2020-01-01
EP2616069A1 (en) 2013-07-24
BR112013006320B1 (pt) 2022-08-30
CN103200942A (zh) 2013-07-10
PT3053576T (pt) 2018-10-08
ES2760920T3 (es) 2020-05-18
US8492557B2 (en) 2013-07-23
HK1257416A1 (zh) 2019-10-18
ES2607084T3 (es) 2017-03-29
CA2811559A1 (en) 2012-03-22
MY168763A (en) 2018-12-04
CA2812191C (en) 2021-04-13
SI3338777T1 (sl) 2020-08-31
IL225278A0 (en) 2013-06-27
ES2687420T3 (es) 2018-10-25
TW201240661A (en) 2012-10-16
DK3053576T3 (da) 2018-08-20
CA2812191A1 (en) 2012-03-22
KR20190022895A (ko) 2019-03-06
MY161607A (en) 2017-04-28
DK3338777T3 (da) 2020-04-20
RU2013116403A (ru) 2014-10-27
WO2012037499A1 (en) 2012-03-22
SG188570A1 (en) 2013-04-30
TR201909249T4 (tr) 2019-07-22
CN103209694A (zh) 2013-07-17
EP3636263B1 (en) 2021-11-03
PT3050564T (pt) 2019-12-11
CL2013000735A1 (es) 2013-11-29
MX2013003004A (es) 2013-06-28
PL2616068T3 (pl) 2016-11-30
KR101840501B1 (ko) 2018-05-04
RU2612351C2 (ru) 2017-03-07
EP3050564A1 (en) 2016-08-03
CN105412092B (zh) 2020-11-17
MY173846A (en) 2020-02-24
EP2616068B1 (en) 2016-07-13
HK1185540A1 (zh) 2014-02-21
PL3050563T3 (pl) 2018-12-31
IL225282A0 (en) 2013-06-27
EP3050564B1 (en) 2019-09-04
CA3116249A1 (en) 2012-03-22
EP2616066B1 (en) 2016-07-13
CA2812195A1 (en) 2012-03-22
TWI591058B (zh) 2017-07-11
PT2616068T (pt) 2016-09-13
PT3348264T (pt) 2020-04-02
US20150148394A1 (en) 2015-05-28
EP2616068A1 (en) 2013-07-24
JP2013540749A (ja) 2013-11-07
CY1122809T1 (el) 2021-05-05
WO2012037484A1 (en) 2012-03-22
EP2616067B1 (en) 2016-05-18
KR101840500B1 (ko) 2018-03-20
EP2616069B1 (en) 2016-11-16
KR20200044147A (ko) 2020-04-28
ES2613509T3 (es) 2017-05-24
IL225278A (en) 2015-11-30
PT3338777T (pt) 2020-05-06
NZ608751A (en) 2015-04-24
ZA201302193B (en) 2013-11-27
DK2616068T3 (da) 2016-08-29
CA3077732A1 (en) 2012-03-22
JP2013541527A (ja) 2013-11-14
ES2781681T3 (es) 2020-09-04
DK3050564T3 (da) 2019-11-25
CA3079450A1 (en) 2012-03-22
TW201240662A (en) 2012-10-16
SI3348264T1 (sl) 2020-07-31
US8501796B2 (en) 2013-08-06
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
JP6073229B2 (ja) 2017-02-01
CL2013000736A1 (es) 2013-07-12
MX2013003008A (es) 2013-06-28
AU2011301901A1 (en) 2013-05-02
ZA201302194B (en) 2013-11-27
US20120122945A1 (en) 2012-05-17
PL3050564T3 (pl) 2020-06-01
AU2011301847B2 (en) 2016-02-11
KR101952457B1 (ko) 2019-02-26
BR112013006355A2 (pt) 2016-06-28
SG188572A1 (en) 2013-04-30
KR102354097B1 (ko) 2022-01-20
RU2013116405A (ru) 2014-10-27
CL2013000734A1 (es) 2013-11-08
US20130296394A1 (en) 2013-11-07
RU2013116541A (ru) 2014-10-27
HUE049573T2 (hu) 2020-10-28
JP6045495B2 (ja) 2016-12-14
SG188571A1 (en) 2013-04-30
WO2012037490A1 (en) 2012-03-22
EP2616066A1 (en) 2013-07-24
ES2788051T3 (es) 2020-10-20
PL3338777T3 (pl) 2020-07-13
SI3050564T1 (sl) 2020-02-28
IL225280A0 (en) 2013-06-27
PT2616069T (pt) 2016-12-06
AR083019A1 (es) 2013-01-23
AU2011301932A1 (en) 2013-05-02
AR083018A1 (es) 2013-01-23
SI3053576T1 (sl) 2018-11-30
CY1121024T1 (el) 2019-12-11
HK1185541A1 (zh) 2014-02-21
EP3053576A1 (en) 2016-08-10
CL2013000733A1 (es) 2013-08-23
MX2013003002A (es) 2013-06-28
CA2812197A1 (en) 2012-03-22
HUE048725T2 (hu) 2020-09-28
HUE039090T2 (hu) 2018-12-28
EP3636263A1 (en) 2020-04-15
CN105412092A (zh) 2016-03-23
EP3050563A1 (en) 2016-08-03
ES2684055T3 (es) 2018-10-01
HUE038698T2 (hu) 2018-11-28
PL3053576T3 (pl) 2018-11-30
EP3338777A1 (en) 2018-06-27
US20160354346A1 (en) 2016-12-08
KR20140003407A (ko) 2014-01-09
ZA201302288B (en) 2013-11-27
AU2011301932C1 (en) 2016-09-01
CA2812197C (en) 2024-01-02
PL2616069T3 (pl) 2017-04-28
PT3050563T (pt) 2018-10-01
ES2904479T3 (es) 2022-04-05
US20130289088A1 (en) 2013-10-31
PL3348264T3 (pl) 2020-08-24
KR20200091507A (ko) 2020-07-30
HK1185539A1 (zh) 2014-02-21
EP3078376A1 (en) 2016-10-12
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
TW201305116A (zh) 2013-02-01
KR102139905B1 (ko) 2020-07-31
UA112973C2 (uk) 2016-11-25
JP2013537236A (ja) 2013-09-30
KR20130114140A (ko) 2013-10-16
US8853251B2 (en) 2014-10-07
EP3338777B1 (en) 2020-02-05
US20140057958A1 (en) 2014-02-27
HK1185538A1 (zh) 2014-02-21
US20120142746A1 (en) 2012-06-07
AU2011301932B2 (en) 2016-02-25
DK3636263T3 (da) 2022-01-10
EP3078376B1 (en) 2019-03-27
AU2011301856C1 (en) 2016-09-08
EP3053576B1 (en) 2018-05-16
AU2011301901B2 (en) 2016-02-11
CY1122958T1 (el) 2021-10-29
HUE047476T2 (hu) 2020-04-28
AU2011301847A1 (en) 2013-05-02
EP2616067A1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
DK3078376T3 (da) Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
CY2020014I1 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
DK2346509T3 (da) Inhalation af levofloxacin til at reducere lungeinflammation
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2513063T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-/1-aryl-5-pyrazolcarboxylsyrederivater
DK2462098T3 (da) Fremgangsmåde til fremstillingen af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
HK1246204B (zh) 包含(3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基)甲醇的藥物組合物
DK2310017T3 (da) Nifurtimox til behandling af sygdomme fremkaldt af trichomonadida
FR2967657B1 (fr) Distributeur unitaire de capsules de beaute
SMT201500123B (it) Dosaggio unitario di apadenoson
DK3093017T3 (da) Farmaceutisk sammensætning omfattende (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol til behandling af optisk neuropati
PL2585445T3 (pl) Polimorfy aktywnego składnika farmaceutycznego